Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy (YELLOW Trial)
ID Number 09-1294Principal Investigator(s)
Annapoorna S Kini
Department(s) or Division(s)
The Zena and Michael A. Wiener Cardiovascular Institute
The purpose of this study is to compare the effects of statin therapy with Rosuvastatin (Crestor) versus the standard statin therapies of Atorvastatin (Lipitor) and Simvastatin (Zocor) on lowering your cholesterol levels. Each of these statin therapies is Food and Drug Administration (FDA) approved, however Rosuvastatin (Crestor) is considered a more aggressive therapy than the others to be used in this study. We will measure by Lipiscan, a device approved by the FDA for use as a tool to identify plaque (cell and fat buildup) in the blood vessels of your heart.
Recruiting Patients: Yes